ANDERSON David W.
No ORCID on file
· 22 papers in corpus
· active 2000-2001
Frequent coauthors
- BHAGWAT Shripad S. 22
- DOUBLEDAY Mary 22
- GAYO Leah M. 22
- JALLURI Ravi Kumar 22
- KOIS Adam 22
- KHAMMUNGKHUNE Sak 22
- MCKIE Jeffrey A. 22
- SHEVLIN Graziella I. 22
- STEIN Bernd M. 22
- SUTHERLAND May S. 22
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…